China NDA Acceptance-Savolitinib in Gastric Cancer

Summary by AI BETAClose X

HUTCHMED announced that its New Drug Application for savolitinib, a treatment for gastric cancer patients with MET amplification, has been accepted with priority review status by the China National Medical Products Administration. This acceptance is based on positive Phase II registration study data in Chinese patients, following a Breakthrough Therapy Designation granted in 2023. Savolitinib has the potential to be the first selective MET inhibitor approved in China for this specific patient population, which accounts for an estimated 4-6% of gastric cancer cases, or approximately 18,000 new cases annually in China.

Disclaimer*

UK 100

Latest directors dealings